Taribavirin Phase 2 Dose Finding Study for the Treatment of Hepatitis C Virus (HCV)
Completed · Phase 2
Conditions studied: Chronic Hepatitis C
In brief
The objective of the study is to select an optimal dose of taribavirin by comparing the efficacy and safety of 3 taribavirin dose levels, 20, 25, and 30 mg/kg/day, versus ribavirin 800 to 1400 mg/day based on body weight, both administered in combination with peginterferon alfa-2b to therapy-naive patients with chronic Hepatitis C Virus (HCV) genotype 1 infection.
Key facts
- Study ID
- NCT00446134
- Run by
- Bausch Health Americas, Inc.
- People needed
- 278
- Starts
- 2007-03-01
- Expected to finish
- 2009-04-01
- Last updated by the study team
- 2012-07-27
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Cedars-Sinai Medical Center, 8635 W. 3rd Street, Suite 590W — Los Angeles, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.